Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022
This report describes the Advisory Committee on Immunization Practice recommendations for administering the pneumococcal conjugate vaccine to U.S. adults. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - January 27, 2022 Category: American Health Tags: Adult Health Adult Vaccinations Advisory Committee on Immunization Practices (ACIP) MMWR Morbidity & Mortality Weekly Report Vaccine-Preventable Diseases and Specific Vaccines Pneumococcal Disease Source Type: news
Covax, the Developing World ’ s Hope against COVID, Has Made It Only Halfway
Delivery of syringes for the vaccination campaign in El Salvador. Latin American countries have made steady progress in immunizing their populations, partly through direct negotiations between their governments and suppliers and partly through international cooperation. CREDIT: PAHO
By Humberto MárquezCARACAS, Jan 20 2022 (IPS) The Covax initiative, the hope of the countries of the developing South to immunize their populations against COVID-19, only met half of its goals in 2021. And as 2022 begins, and the omicron variant of the virus is spreading fast, the scheme still depends on the decisions of pharmaceutical compani...
Source: IPS Inter Press Service - Health - January 20, 2022 Category: International Medicine & Public Health Authors: Humberto Marquez Tags: COVID-19 Development & Aid Editors' Choice Featured Global Global Governance Headlines Health Humanitarian Emergencies Regional Categories TerraViva United Nations COVAX COVID-19 vaccines Source Type: news
Don ’t demonise those who refuse the Covid vaccine | Letters
One reader ’s experience of the effects on family members of the conspiracy theories surrounding vaccinationsI read David Green ’sletter on anti-vaxxers (12 January) and empathised with theletter written in response (13 January). The week before Christmas my dad died of Covid. The intensive care consultant couldn ’t have been clearer that, in her opinion, if he had been vaccinated he would not have developed Covid pneumonia to the severity that he did.He died very frightened and asking his family to come and be with him, and we couldn ’t. The experience traumatised my sister so badly that she was hospitalised with ...
Source: Guardian Unlimited Science - January 16, 2022 Category: Science Authors: Letters Tags: Coronavirus Vaccines and immunisation Health Infectious diseases Medical research Science Society Source Type: news
Pfizer study shows COVID-19 booster can be co-administered with pneumonia shot
The data provides evidence supporting the potential to administer pneumonia shot, PREVNAR 20, and the company's COVID-19 vaccine at the same time, reducing the number of visits people make to doctors or pharmacies for recommended immunization, Pfizer said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 12, 2022 Category: Pharmaceuticals Source Type: news
Roche COVID-19 At-Home Test granted FDA Emergency Use Authorization to expand access to rapid self-testing solutions in the United States
Rapid test to support the American public ’s fight against the COVID-19 pandemic, with availability to purchase over-the-counter (OTC) at pharmacies and retailers nationwideThe COVID-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron.EUA granted through Roche ’s participation in the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Independent Test Assessment Program to bring rapid tests to the OTC marketBasel, 24 ...
Source: Roche Media News - December 24, 2021 Category: Pharmaceuticals Source Type: news
Pathogenicity and virulence of Staphylococcus aureus
Staphylococcus aureus is one of the most frequent worldwide causes of morbidity and mortality due to an infectious agent. This pathogen can cause a wide variety of diseases, ranging from moderately severe skin infections to fatal pneumonia and sepsis. Treatment of S. aureus infections is complicated by antibiotic resistance and a working vaccine is not available. There has been ongoing and increasing interest in the extraordinarily high number of toxins and other virulence determinants that S. aureus produces and how they impact disease. In this review, we will give an overview of how S. aureus initiates and maintains infe...
Source: Current Awareness Service for Health (CASH) - December 14, 2021 Category: Consumer Health News Source Type: news
New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the RP2D,...
Source: Johnson and Johnson - December 13, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC) Pha...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from two studies evaluating the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) as a potential fixed-duration treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These data were both featured today during the American Society of Hematology (ASH) 2021 Annual Meeting. New secondary endpoint data from the Phase 3 GLOW study (NCT03462719) showed that fixed-duration treatment with I+V resulted in undetectable min...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Latest Phase 3 Data for First-in-Class TREMFYA ® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus placeb...
Source: Johnson and Johnson - December 3, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Gates Foundation to invest up to $90M in vaccine maker Inventprise
Redmond-based vaccine maker Inventprise is gaining serious backing from the Bill& Melinda Gates Foundation.
On Wednesday, the biotech company announced an investment from the foundation of up to $90 million, contingent on manufacturing, clinical and preclinical milestones. The foundation is investing in IVT-25, a vaccine targeting pneumococcal bacterial infections. Pneumococcus can cause infections like pneumonia and meningitis.
"High rates of morbidity and mortality due to pneumococcal disease… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 10, 2021 Category: American Health Authors: Rick Morgan Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Why You Should Vaccinate Your Kids Against COVID-19
It’s time for my healthy nine-year-old son to get vaccinated against COVID-19. In fact, it’s time for every kid aged five to eleven to get vaccinated.
An advisory committee to the Food and Drug Administration (FDA) has reviewed the data from clinical trials assessing the safety and efficacy of the Pfizer-BioNTech vaccine in children five to eleven years old. The experts voted unanimously to recommend authorization for this vaccine in children in that age range. As a next step, the Centers for Disease Control and Prevention (CDC) will decide whether all kids should have access to the vaccine, or only some. Some ...
Source: TIME: Health - October 30, 2021 Category: Consumer Health News Tags: Uncategorized COVID-19 Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
ACIP Expands Shingrix Recs; Updates Pneumococcal Vax Guidance ACIP Expands Shingrix Recs; Updates Pneumococcal Vax Guidance
The committee voted to recommend that immunocompromised adults aged 19+ be vaccinated against shingles, and that adults with certain risk factors or aged 65 and older receive a pneumococcal vaccine.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 22, 2021 Category: Internal Medicine Tags: Infectious Diseases News Source Type: news
